Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients

EJNMMI Research

Table 2 Individual patient characteristics

Patient	Age	Sex	Primary tumor	TNM	Grade	Ki-67 index	Ongoing therapies	First scan	Scan interval (days)	Time between scan and therapy (days)
Patient	Age	Sex	Primary tumor	TNM	Grade	Ki-67 index	Ongoing therapies	First scan	Scan interval (days)	F-18	Ga-68
1	64	M	Pancreas	T0N1M1c	G2	2–10%	SSA, everolimus	[⁶⁸Ga]Ga-DOTATATE	16	45	61
2	54	V	Pancreas	T2N0M1c	G2	18%	SSA	[⁶⁸Ga]Ga-DOTATATE	22	46	68
3	61	M	Pancreas	T0N1M1c	G2	10%	/	[⁶⁸Ga]Ga-DOTATATE	14	/	/
4	71	V	Pancreas	T2N0M0	G1	2%	/	[⁶⁸Ga]Ga-DOTATATE	13	/	/
5	60	V	Small Intestine	T0N1M1c	G2	8%	SSA	[⁶⁸Ga]Ga-DOTATATE	4	41	45
6	60	M	Small Intestine	T0N1M1c	G1	1%	SSA	[¹⁸F]AlF-OC	1	40	39
7	48	M	Lung	T0N3M1c	G1/G2	< 5%	SSA	[¹⁸F]AlF-OC	8	35	27
8	38	M	Lung	T0N0M1b	G2	5%	SSA	[⁶⁸Ga]Ga-DOTATATE	35	54	89
9	57	V	CUP	T0N0M1b	G2	7%	SSA, everolimus	[⁶⁸Ga]Ga-DOTATATE	6	20	26
10	65	M	CUP	T0N1M1a	G1/G2	< 5%	SSA	[⁶⁸Ga]Ga-DOTATATE	4	37	41